PLAN-B NET ZERO integrates measurable impact into electricity tariffs and expands partnership with everwave
mehr
Storys aus Aachen
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
mehrGrünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
Aachen, Germany (ots) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. - Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 ...
mehrGrünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
mehrGrünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
mehrFEV analysis: TCO cut by up to 33 percent through range extender trucks
mehr
Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
mehrDaimler Buses teams up with FEV to launch the first hydrogen-powered Setra demonstrator vehicle
mehrHenkel kicks off its anniversary year 2026
mehrFraunhofer-Institut für Produktionstechnologie IPT
3The future of 5G and 6G technology in industry: Completion of the EU project “TARGET-X”
mehrFEV expands portfolio with advanced robotics and bundles expertise for sustainable and economical applications
mehrFraunhofer-Institut für Produktionstechnologie IPT
More power in a smaller space: Compact press system for manufacturing hydrogen components
mehr
FEV and Nature Architects collaborate on the development of AI-supported, innovative vehicle structures
mehrFEV and Chiyoda combine expertise for sustainable energy solutions
mehr- 5
PM: Ein elektrisches Jahrhundert: Wie sich Post-Fahrzeuge in Deutschland weiterentwickelt haben / PR: An electric century: The evolution of postal vehicles in Germany
mehr Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
mehrGenerative AI accelerates homologation: FEV simplifies country-specific type approval processes
mehrFraunhofer-Institut für Produktionstechnologie IPT
Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production
mehr
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
mehrMaren Thurow starts as new Head Global Communications at Grünenthal
mehr- 2
urbanOS: The World's First Operating System for Smart Cities
mehr - 2
Press Release - hubergroup takes BOPE films to a new level with the new Gecko 2-Component Varnish
Ein Dokumentmehr Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
mehr- 3
High-temperature heat pump for Südzucker subsidiary Tiense Suiker
mehr
FEV develops AI-supported driver monitoring system CogniSafe
mehrGrünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
mehrFEV and ProLogium develop high-performance vehicle battery
mehrGrünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
mehrFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
2Deep learning for real-time quality control: Aachen-based Fraunhofer Institutes improve defect detection in weld seams
mehr
12Nächste